{"id":"W3152739953","doi":"10.1016/j.clgc.2021.04.008","title":"Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"Janssen Pharmaceuticals; EMD Serono; Genentech; National Institutes of Health; Bavarian Nordic; Bayer Schering; Astellas Pharma; Eisai; Cancer Research UK; GlaxoSmithKline; Virginia Marine Resources Commission; Advanced Accelerator Applications; Bayer Fund; Clovis Oncology; Meso Scale Diagnostics; Les Laboratories Pierre Fabre; Jounce Therapeutics; Merck Sharp and Dohme; Genzyme; National Institute on Handicapped Research; Exelixis; Sanofi; Novartis; Merck; Heron Therapeutics; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; Roche; Astellas Pharma US; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Internal medicine; Pembrolizumab; Durvalumab; Oncology; Atezolizumab; Metastatic Urothelial Carcinoma; Carboplatin; Cisplatin; Response Evaluation Criteria in Solid Tumors; Retrospective cohort study; Urology; Bladder cancer; Urothelial carcinoma; Cancer; Chemotherapy; Progressive disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001981665,0.0005199944,0.001579781,0.0000933121,0.0001219848,0.00001669787,0.0001786407,0.0003111822,0.0005046478],"category_scores_gemma":[0.0002398114,0.0003414629,0.0005079704,0.0005034239,0.0004050639,0.0001405359,0.0001168338,0.000575525,0.00002974573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001307148,"about_ca_system_score_gemma":0.001260428,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002150209,"about_ca_topic_score_gemma":0.0002714776,"domain_scores_codex":[0.9960758,0.0001790303,0.001556046,0.0009780913,0.0006737977,0.0005372108],"domain_scores_gemma":[0.9967464,0.0006035767,0.0004891958,0.0008586812,0.0007847939,0.0005174037],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009544162,0.003378747,0.9659949,0.0001373988,0.0009622189,0.0004737128,0.00004729798,0.00007007566,0.00002728054,0.000002065506,0.001129433,0.01823271],"study_design_scores_gemma":[0.03051779,0.008256713,0.9524329,0.0004019225,0.0009858726,0.00002027944,0.00004286557,0.00001597209,0.001815108,0.00001328062,0.005096117,0.0004011487],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947761,0.0007846003,0.00002859695,0.0006634106,0.000739531,0.001020083,0.0002999318,0.00009340243,0.00159433],"genre_scores_gemma":[0.9923544,0.0009742547,0.001687335,0.0009448576,0.0009896711,0.0001631434,0.0001731195,0.0001156939,0.002597537],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02097363,"threshold_uncertainty_score":0.9999037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03517358340460927,"score_gpt":0.3511806430000108,"score_spread":0.3160070595954015,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}